Difference between revisions of "Cladribine (Leustatin)"
Jump to navigation
Jump to search
m |
m |
||
Line 1: | Line 1: | ||
− | |||
− | |||
==General information== | ==General information== | ||
Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.<ref name="insert">[http://www.janssenbiotech.com/assets/Leustatin_PI.pdf Cladribine (Leustatin)) package insert]</ref><ref>[[Media:Cladribine.pdf | Cladribine (Leustatin) package insert (locally hosted backup)]]</ref> | Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.<ref name="insert">[http://www.janssenbiotech.com/assets/Leustatin_PI.pdf Cladribine (Leustatin)) package insert]</ref><ref>[[Media:Cladribine.pdf | Cladribine (Leustatin) package insert (locally hosted backup)]]</ref> | ||
Line 7: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
==Patient drug information== | ==Patient drug information== | ||
*[http://chemocare.com/chemotherapy/drug-info/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/cladribine.aspx Cladribine (Leustatin) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cladribine-patient-drug-information Cladribine (Leustatin) patient drug information (UpToDate)]</ref> | ||
+ | |||
+ | ==Also known as== | ||
+ | 2-chlorodeoxyadenosine, 2-CdA, Litak, Movectro | ||
==References== | ==References== | ||
Line 27: | Line 22: | ||
[[Category:Irritant chemotherapy]] | [[Category:Irritant chemotherapy]] | ||
[[Category:Nucleic acid analogs]] | [[Category:Nucleic acid analogs]] | ||
+ | |||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | [[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | ||
+ | [[Category:Hairy cell leukemia medications]] | ||
+ | [[Category:Marginal zone lymphoma medications]] |
Revision as of 20:41, 11 June 2014
General information
Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Cladribine (Leustatin) patient drug information (Chemocare)[3]
- Cladribine (Leustatin) patient drug information (UpToDate)[4]
Also known as
2-chlorodeoxyadenosine, 2-CdA, Litak, Movectro